Home › Funds › Soleus Capital Management, L.P. › PHVS
Soleus Capital Management, L.P. position in PHVS
PHARVARIS N V · Health Care
Soleus Capital Management, L.P. reported holding 730,907 shares of PHVS (PHARVARIS N V) in its Q2 2026 13F filing — a position valued at US$25.3M, representing 0.87% of its reported portfolio and ranking #32 among its reported holdings. Soleus Capital Management, L.P. has disclosed PHVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s PHVS position evolved
Soleus Capital Management, L.P. first disclosed a stake in PHVS in Q3 2023 at 343,975 shares (US$7.2M). The position peaked in Q2 2026 at 730,907 shares, worth US$25.3M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 730,907 shares valued at US$25.3M — an increase of 28,855 shares quarter over quarter.. Notable position changes include a 37% trim in Q4 2023 (shares fell 33% over the following quarter), a 85% increase in Q1 2024, a 50% increase in Q3 2024.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 343.98K | $7.18M | New |
| Q4 2023 | 217.40K | $6.10M | Reduce |
| Q1 2024 | 401.90K | $9.29M | Add |
| Q2 2024 | 399.43K | $7.51M | Reduce |
| Q3 2024 | 598.17K | $11.08M | Add |
| Q4 2024 | 814.65K | $15.62M | Add |
| Q1 2025 | 814.65K | $12.79M | Hold |
| Q2 2025 | 732.97K | $12.90M | Reduce |
| Q3 2025 | 647.05K | $16.14M | Reduce |
| Q4 2025 | 702.05K | $19.48M | Add |
| Q1 2026 | 702.05K | $19.83M | Hold |
| Q2 2026 | 730.91K | $25.27M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PHVS and 13F data
PHVS (PHARVARIS N V) is a Health Care company. 49 other funds we track also report a position in PHVS — the largest reported positions include GENERAL ATLANTIC, L.P. (US$226.5M), Foresite Capital Management IV, LLC (US$165.2M), venBio Partners LLC (US$160.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PHVS
- GENERAL ATLANTIC, L.P. 6.55M sh · $226.53M · Q2 2026
- Foresite Capital Management IV, LLC 4.78M sh · $165.24M · Q2 2026
- venBio Partners LLC 4.64M sh · $160.57M · Q2 2026
- EQT Fund Management S.a r.l. 3.42M sh · $118.42M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.38M sh · $116.74M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 2.68M sh · $92.52M · Q2 2026
- Commodore Capital LP 1.43M sh · $49.28M · Q2 2026
- Novo Holdings A/S 1.40M sh · $48.41M · Q2 2026
- Saturn V Capital Management LP 1.31M sh · $45.44M · Q2 2026
- TCG Crossover Management, LLC 1.01M sh · $34.86M · Q2 2026
- Sofinnova Investments, Inc. 881.30K sh · $30.48M · Q2 2026
- 5AM Venture Management, LLC 797.60K sh · $27.58M · Q2 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held PHVS?
Soleus Capital Management, L.P. has disclosed PHVS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Soleus Capital Management, L.P.'s current position in PHVS?
As of Q2 2026, Soleus Capital Management, L.P. holds 730.91K shares of PHVS (PHARVARIS N V), valued at $25.27M, representing 0.87% of its reported portfolio and ranking #32.
Has Soleus Capital Management, L.P. been buying or selling PHVS?
In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in PHVS. The position peaked in Q2 2026 at 730.91K shares.
Which other funds hold PHVS?
Other major institutional holders of PHVS include GENERAL ATLANTIC, L.P., Foresite Capital Management IV, LLC, venBio Partners LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.